Patents Assigned to The Regents of California
  • Publication number: 20230181607
    Abstract: Disclosed herein, inter alia, are methods of using thiosaccharide compounds for treating coronavirus infection.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicants: The University of the Regents of California, University College Dublin
    Inventors: John Vincent Fahy, Irina Gitlin, Wilfred Raymond, Stefan Oscarson
  • Patent number: 10580591
    Abstract: A metal oxide anchored graphene and carbon nanotube hybrid foam can be formed via a two-step process. The method can include forming at least one graphene layer and a plurality of carbon nanotubes onto a surface of a porous metal substrate by chemical vapor deposition to form a coated porous metal substrate, and depositing a plurality of metal oxide nanostructures onto a surface of the coated porous metal substrate to form the metal oxide anchored graphene and carbon nanotube hybrid foam.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: March 3, 2020
    Assignee: THE REGENTS OF CALIFORNIA, RIVERSIDE
    Inventors: Wei Wang, Shirui Guo, Cengiz S Ozkan, Mihrimah Ozkan
  • Patent number: 7662785
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: February 16, 2010
    Assignees: The Regents of California, Lawrence Livermore National Security, LLC
    Inventors: Sally DeNardo, Gerald DeNardo, Rodney Balhorn
  • Patent number: 7335744
    Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: February 26, 2008
    Assignee: The Regents of the California University
    Inventors: Bin Liu, James D. Marks
  • Patent number: 7332585
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: February 19, 2008
    Assignees: The Regents of the California University, Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Patent number: 6573997
    Abstract: A new interferometry configuration combines the strengths of two existing interferometry methods, improving the quality and extending the dynamic range of both. On the same patterned mask, placed near the image-plane of an optical system under test, patterns for phase-shifting point diffraction interferometry and lateral shearing interferometry coexist. The former giving verifiable high accuracy for the measurement of nearly diffraction-limited optical systems. The latter enabling the measurement of optical systems with more than one wave of aberration in the system wavefront.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: June 3, 2003
    Assignee: The Regents of California
    Inventors: Kenneth Alan Goldberg, Patrick P. Naulleau
  • Publication number: 20020127239
    Abstract: An antigenic preparation is provided containing an outer membrane protein associated with pathogenic strains of Leptospira. The protein has been designated ALipL32″ for Alipoprotein from Leptospira≅ and because the isolated polypeptide migrates to a position corresponding to a molecular weight of 32 kD in a denaturing polyacrylamide gel. The invention provides polynucleotides encoding LipL32 and antibodies that bind the protein which are useful in the diagnosis of leptospirosis. In addition, LipL32 can be used immunologically as a vaccine for spirochete-associated pathologies.
    Type: Application
    Filed: August 8, 2001
    Publication date: September 12, 2002
    Applicant: The Regents of California University
    Inventor: David A. Haake
  • Patent number: 5658545
    Abstract: The present invention relates to a process of using metal particles to reduce NO to NH.sub.3. More specifically, the invention concerns an improved process to regenerate iron (II) (CHELATE) by reduction of iron (II) (CHELATE) (NO) complex, which process comprises: a) contacting an aqueous solution containing iron (II) (CHELATE) (NO) with metal particles at between about 20.degree. and 90.degree. C. to reduce NO present, produce ammonia or an ammonium ion, and produce free iron (II) (CHELATE) at a pH of between about 3 and 8. The process is useful to remove NO from flue gas and reduce pollution.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: August 19, 1997
    Assignee: The Regents of California
    Inventors: Shih-Ger Chang, David Littlejohn, Yao Shi